tert-butyl (3S,4S)-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate | 1417789-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (3S,4S)-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate
• 英文别名: tert-butyl (3S,4S)-3-(hydroxymethyl)-4-methyl-pyrrolidine-1-carboxylate
• CAS: 1417789-75-3
• 化学式: C₁₁H₂₁NO₃
• 分子量: 215.293
• InChiKey: QNVPXIMDUBAIPY-BDAKNGLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (3S,4S)-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate 、 甲基磺酸酐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 tert-butyl (3S,4S)-3-methyl-4-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] APOL1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS D'APOL1 ET MÉTHODES D'UTILISATION

  摘要：

  Provided herein are compounds of formula (A'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, X3, X4, Ra, Rb, Rc, L, Q, and Y are as defined herein. Also provided are methods of inhibiting APOL1 and methods of preparing compounds of formula (A'). Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.

  公开号：

  WO2022178315A1
• 作为产物：
  描述：

  (S,S)-trans-4-methylpyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 在 diborane(6) 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 tert-butyl (3S,4S)-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] APOL1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS D'APOL1 ET MÉTHODES D'UTILISATION

  摘要：

  Provided herein are compounds of formula (A'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, X3, X4, Ra, Rb, Rc, L, Q, and Y are as defined herein. Also provided are methods of inhibiting APOL1 and methods of preparing compounds of formula (A'). Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.

  公开号：

  WO2022178315A1

文献信息

• 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS
  申请人：MISSION THERAPEUTICS LIMITED

  公开号：US20200331888A1

  公开（公告）日：2020-10-22

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R 1a , R 1b , R 1c , R 1d , R 1e and R 1f each independently represent hydrogen, optionally substituted C 1 -C 6 alkyl or optionally substituted C 3 -C 4 cycloalkyl, or R 1b and R 1c together form an optionally substituted C 3 -C 6 cycloalkyl ring, or R 1d and R 1e together form an optionally substituted C 3 -C 6 cycloalkyl ring; R 2 represents hydrogen or optionally substituted C 1 -C 6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

  本发明涉及新化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C-末端水解酶30或泛素特异性肽酶30（USP30）。这些新化合物的化学式为（I）：（化学式（I）），或其药学上可接受的盐，其中：R1a，R1b，R1c，R1d，R1e和R1f分别独立地代表氢，可选择地取代的C1-C6烷基或可选择地取代的C3-C4环烷基，或者R1b和R1c共同形成一个可选择地取代的C3-C6环烷基环，或者R1d和R1e共同形成一个可选择地取代的C3-C6环烷基环；R2代表氢或可选择地取代的C1-C6烷基；A代表一个可选择地进一步取代的5到10个成员的单环或双环杂环芳基，杂环烷基或芳基环；L代表一个共价键或连接物；B代表一个可选择地取代的3到10个成员的单环或双环杂环烷基，杂环芳基，环烷基或芳基环；当-A-L-B位于位置x时，通过A的一个碳环原子连接到A，且：A不能是三唑吡啶基，三唑吡啉基，咪唑三嗪基，咪唑吡嗪基或吡咯嘧啶基；或者B不能被苯氧基取代；或者当L是氧原子时，B不能是环戊基。
• PYRROLOPYRIMIDINE AND PURINE DERIVATIVES
  申请人：Cheng Hengmiao

  公开号：US20130079324A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新颖的吡咯嘧啶和嘌呤衍生物在哺乳动物中治疗异常细胞生长，如癌症方面具有用处。另外，本发明还涉及含有这些化合物的药物组合物，以及在哺乳动物中治疗异常细胞生长的方法。
• Pyrrolopyrimidine and purine derivatives
  申请人：Cheng Hengmiao

  公开号：US09040547B2

  公开（公告）日：2015-05-26

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新型吡咯吡嗪和嘌呤衍生物在哺乳动物的异常细胞生长，如癌症治疗中有用。另外，还涉及含有这些化合物的制药组合物以及在哺乳动物的异常细胞生长治疗中使用这些化合物和组合物的方法。
• 1-cyano-pyrrolidine derivatives as DUB inhibitors
  申请人：MISSION THERAPEUTICS LIMITED

  公开号：US11352339B2

  公开（公告）日：2022-06-07

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R1a, R1b, R1c, R1d, R1e and R1f each independently represent hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C4 cycloalkyl, or R1b and R1c together form an optionally substituted C3-C6 cycloalkyl ring, or R1d and R1e together form an optionally substituted C3-C6 cycloalkyl ring; R2 represents hydrogen or optionally substituted C1-C6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

  本发明涉及新型化合物和制造去泛素化酶（DUB）抑制剂的方法。特别是，本发明涉及对泛素 C 端水解酶 30 或泛素特异性肽酶 30（USP30）的抑制。新型化合物具有式（I）：式（I））或其药学上可接受的盐，其中：R1a、R1b、R1c、R1d、R1e 和 R1f 各自独立地代表氢、任选取代的 C1-C6 烷基或任选取代的 C3-C4 环烷基，或 R1b 和 R1c 一起形成任选取代的 C3-C6 环烷基环，或 R1d 和 R1e 一起形成任选取代的 C3-C6 环烷基环；R2 代表氢或任选取代的 C1-C6 烷基；A 代表任选被进一步取代的 5 至 10 个成员的单环或双环杂芳基、杂环烷基或芳基环；L 代表共价键或连接体；B 代表任选被取代的 3 至 10 个成员的单环或双环杂环烷基、杂芳基、环烷基或芳基环；当 -A-L-B 位于 x 位时，通过 A 的碳环原子与 A 连接，且任选其一：A 不能是三唑哒嗪基、三唑吡啶基、咪唑三嗪基、咪唑吡嗪基或吡咯嘧啶基；或 B 不能被苯氧基取代；或当 L 为氧原子时，B 不能是环戊基。
• 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS
  申请人：Mission Therapeutics Limited

  公开号：EP3433246B1

  公开（公告）日：2022-05-04